You are here: Home » PTI Stories » National » News
Business Standard

Sun Pharma, ICGEB ink pact to develop dengue vaccine

Press Trust of India  |  New Delhi 

Drug major today announced a new collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) for development of dengue vaccine targeted against all four serotypes of the virus.

This is the second collaboration between and ICGEB focusing on dengue. The first one was related to the development of a botanical drug for treatment of dengue.



As per the agreement, will fund and support further development of the vaccine candidate and existing ICGEB know-how and patents, and ICGEB said.

ICGEB will grant exclusive rights and licences for development and commercialisation of this vaccine globally, they added.

"Healthcare industry is all about innovation. We are now looking at prevention of dengue. Our partnership is for developing a novel, safe, effective and affordable preventive vaccine," Executive V-P and Head, Global Business Development, Kirti Ganorkar told reporters here.

The new collaboration with ICGEB for developing an affordable dengue vaccine is part of the broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world, he added.

"Our decision to partner with ICGEB on dengue vaccine programme followed extensive due diligence and expert consultations on existing dengue vaccine programmes globally," Ganorkar said.

ICGEB has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for this dengue vaccine candidate.

"Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations," ICGEB Director Dinakar Salunke said.

A joint development committee comprising members of both the organisations will be set up to provide oversight to the dengue vaccine development programme, ICGEB and said in a joint statement.

As per the agreement, "ICGEB will receive pre-defined royalty and milestone payments".

"ICGEB shall disclose and make available to all such existing ICGEB know-how as well as effective completion of technology transfer by ICGEB to within stipulated timeframe," the statement added.

will explore commercialisation opportunities to provide this vaccine to patients across India, emerging markets, Western Europe, Japan and USA at affordable costs post regulatory approvals in these markets.

The company will use its in-house expertise as well as that of its associate company, ARTES Biotechnology GmbH, in development of dengue vaccine, said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Sun Pharma, ICGEB ink pact to develop dengue vaccine

Drug major Sun Pharma today announced a new collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) for development of dengue vaccine targeted against all four serotypes of the virus. This is the second collaboration between Sun Pharma and ICGEB focusing on dengue. The first one was related to the development of a botanical drug for treatment of dengue. As per the agreement, Sun Pharma will fund and support further development of the vaccine candidate and existing ICGEB know-how and patents, Sun Pharma and ICGEB said. ICGEB will grant Sun Pharma exclusive rights and licences for development and commercialisation of this vaccine globally, they added. "Healthcare industry is all about innovation. We are now looking at prevention of dengue. Our partnership is for developing a novel, safe, effective and affordable preventive vaccine," Sun Pharma Executive V-P and Head, Global Business Development, Kirti Ganorkar told reporters here. ... Drug major today announced a new collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) for development of dengue vaccine targeted against all four serotypes of the virus.

This is the second collaboration between and ICGEB focusing on dengue. The first one was related to the development of a botanical drug for treatment of dengue.

As per the agreement, will fund and support further development of the vaccine candidate and existing ICGEB know-how and patents, and ICGEB said.

ICGEB will grant exclusive rights and licences for development and commercialisation of this vaccine globally, they added.

"Healthcare industry is all about innovation. We are now looking at prevention of dengue. Our partnership is for developing a novel, safe, effective and affordable preventive vaccine," Executive V-P and Head, Global Business Development, Kirti Ganorkar told reporters here.

The new collaboration with ICGEB for developing an affordable dengue vaccine is part of the broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world, he added.

"Our decision to partner with ICGEB on dengue vaccine programme followed extensive due diligence and expert consultations on existing dengue vaccine programmes globally," Ganorkar said.

ICGEB has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for this dengue vaccine candidate.

"Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations," ICGEB Director Dinakar Salunke said.

A joint development committee comprising members of both the organisations will be set up to provide oversight to the dengue vaccine development programme, ICGEB and said in a joint statement.

As per the agreement, "ICGEB will receive pre-defined royalty and milestone payments".

"ICGEB shall disclose and make available to all such existing ICGEB know-how as well as effective completion of technology transfer by ICGEB to within stipulated timeframe," the statement added.

will explore commercialisation opportunities to provide this vaccine to patients across India, emerging markets, Western Europe, Japan and USA at affordable costs post regulatory approvals in these markets.

The company will use its in-house expertise as well as that of its associate company, ARTES Biotechnology GmbH, in development of dengue vaccine, said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Sun Pharma, ICGEB ink pact to develop dengue vaccine

Drug major today announced a new collaboration with International Centre for Genetic Engineering and Biotechnology (ICGEB) for development of dengue vaccine targeted against all four serotypes of the virus.

This is the second collaboration between and ICGEB focusing on dengue. The first one was related to the development of a botanical drug for treatment of dengue.

As per the agreement, will fund and support further development of the vaccine candidate and existing ICGEB know-how and patents, and ICGEB said.

ICGEB will grant exclusive rights and licences for development and commercialisation of this vaccine globally, they added.

"Healthcare industry is all about innovation. We are now looking at prevention of dengue. Our partnership is for developing a novel, safe, effective and affordable preventive vaccine," Executive V-P and Head, Global Business Development, Kirti Ganorkar told reporters here.

The new collaboration with ICGEB for developing an affordable dengue vaccine is part of the broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world, he added.

"Our decision to partner with ICGEB on dengue vaccine programme followed extensive due diligence and expert consultations on existing dengue vaccine programmes globally," Ganorkar said.

ICGEB has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for this dengue vaccine candidate.

"Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations," ICGEB Director Dinakar Salunke said.

A joint development committee comprising members of both the organisations will be set up to provide oversight to the dengue vaccine development programme, ICGEB and said in a joint statement.

As per the agreement, "ICGEB will receive pre-defined royalty and milestone payments".

"ICGEB shall disclose and make available to all such existing ICGEB know-how as well as effective completion of technology transfer by ICGEB to within stipulated timeframe," the statement added.

will explore commercialisation opportunities to provide this vaccine to patients across India, emerging markets, Western Europe, Japan and USA at affordable costs post regulatory approvals in these markets.

The company will use its in-house expertise as well as that of its associate company, ARTES Biotechnology GmbH, in development of dengue vaccine, said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard